Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VCN 01

Next Previous
X
Search
Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VCN Biosciences
  • Developer AstraZeneca; Theriva Biologics; VCN Biosciences
  • Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenocarcinoma; Retinoblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
  • Phase I Ovarian cancer
  • No development reported Brain cancer; Solid tumours

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Brain-cancer(In adolescents, Late-stage disease, Metastatic disease, Recurrent, In adults) in United Kingdom (IV)
  • 23 Sep 2024 Theriva Biologics completes enrolment in the phase II VIRAGE trial for Adenocarcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Germany, Spain, USA (IV) (EudraCT-2022-000897-24) (NCT05673811)
  • 31 Jul 2024 VCN 01 receives Rare Pediatric Drug Designation (RPDD) for Retinoblastoma in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top